Related Experiment Video
Updated: Jul 18, 2025

Translating Ribosome Affinity Purification TRAP for RNA Isolation from Endothelial Cells In Vivo
Published on: May 25, 2019
Repression of rRNA gene transcription by endothelial SPEN deficiency normalizes tumor vasculature via nucleolar
Abstract:
Human cancers induce a chaotic, dysfunctional vasculature that promotes tumor growth and blunts most current therapies; however, the mechanisms underlying the induction of a dysfunctional vasculature have been unclear. Here, we show that split end (SPEN), a transcription repressor, coordinates rRNA synthesis in endothelial cells (ECs) and is required for physiological and tumor angiogenesis. SPEN deficiency attenuated EC proliferation and blunted retinal angiogenesis, which was attributed to p53 activation. Furthermore, SPEN knockdown activated p53 by upregulating noncoding promoter RNA (pRNA), which represses rRNA transcription and triggers p53-mediated nucleolar stress. In human cancer biopsies, a low endothelial SPEN level correlated with extended overall survival. In mice, endothelial SPEN deficiency compromised rRNA expression and repressed tumor growth and metastasis by normalizing tumor vessels, and this was abrogated by p53 haploinsufficiency. rRNA gene transcription is driven by RNA polymerase I (RNPI). We found that CX-5461, an RNPI inhibitor, recapitulated the effect of Spen ablation on tumor vessel normalization and combining CX-5461 with cisplatin substantially improved the efficacy of treating tumors in mice. Together, these results demonstrate that SPEN is required for angiogenesis by repressing pRNA to enable rRNA gene transcription and ribosomal biogenesis and that RNPI represents a target for tumor vessel normalization therapy of cancer.
Insights
Split end (SPEN), a transcription repressor, is crucial for blood vessel formation in tumors. Inhibiting SPEN normalizes tumor vasculature, repressing cancer growth and metastasis, offering a new therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Biology
- Vascular Biology
Background:
- Human cancers develop chaotic, dysfunctional tumor vasculature, hindering therapeutic efficacy.
- Mechanisms driving tumor vasculature dysfunction remain largely unknown.
Purpose of the Study:
- To elucidate the role of split end (SPEN) in endothelial cells (ECs) and its impact on angiogenesis.
- To investigate SPEN's role in tumor vascularization and identify potential therapeutic targets.
Main Methods:
- Investigated SPEN's function in ECs using knockdown and knockout models.
- Analyzed the effects of SPEN deficiency on angiogenesis, p53 activation, and rRNA synthesis.
- Examined SPEN expression in human cancer biopsies and its correlation with patient survival.
- Utilized RNA polymerase I (RNPI) inhibitor CX-5461 and cisplatin in mouse cancer models.
Main Results:
- SPEN deficiency in ECs attenuated proliferation and angiogenesis, linked to p53 activation via noncoding promoter RNA (pRNA).
- Low endothelial SPEN levels in human cancers correlated with improved overall survival.
- Endothelial SPEN deficiency repressed tumor growth and metastasis in mice by normalizing tumor vessels, dependent on p53.
- RNPI inhibition with CX-5461 mimicked SPEN ablation effects, and combination therapy with cisplatin enhanced anti-tumor efficacy.
Conclusions:
- SPEN is essential for angiogenesis by regulating rRNA gene transcription and ribosomal biogenesis.
- Targeting RNPI offers a promising strategy for tumor vessel normalization therapy in cancer treatment.
More Related Videos
Related Concept Videos
Regulation of Angiogenesis and Blood Supply
The Nucleolus
Regulation of Nuclear Protein Sorting
RNA Splicing
Mechanism of Angiogenesis
Abnormal Proliferation

